Sector
1063 stories · page 37 of 54
Woolworths had proposed to acquire API at a cash offer price of $1.75 a share, however, said it could not validate the financial returns it requires in line with the group’s capital allocation framework.
The company said the net proceeds of the private placement will be used for the expansion of clinics, certain strategic investments and general working capital purposes
"With Mr. Dhaliwal's appointment, Binovi will enhance its access to capital markets and health care industry networks, which will be valuable assets towards the execution on Binovi's strategy and conversion of business prospects,“ said Terr
Managing director Roby Zomer says MGC is “pleased to have the opportunity to alleviate the symptoms of COVID-19 in one of the largest populated countries in the world”
Dr. Corey Hilmas, the chief regulatory officer of its subsidiary KGK Science, will be the board's' interim chair and will serve with new member, Brigadier General (Ret.) Dr. Loree K. Sutton
As the company enters 2022, it is progressing with investigational new drug-enabling studies for its lead candidate MSP-1014
Here are the health sector highlights for the past week.
"Listing on the Frankfurt Stock Exchange will provide Pathway Health with direct access to the European capital markets and an opportunity for the company to increase trading liquidity and facilitate investment by expanding our shareholder
“We are pleased with Ketamine One’s financial results for the first quarter of the 2022 fiscal year, as revenue during the three-month period ending October 31st exceeded that for all of the 2021 fiscal year,” interim CEO Adam Deffett said.
"Mr Ramelli comes to our organization as a highly recommended professional and we are looking forward to learning from his expertise,” said Adam Deffett, Interim CEO of Ketamine One
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
"This remedy offers a potential and innovative treatment avenue for adults with treatment-resistant depression,” said Braxia Scientific CEO Dr Roger McIntyre
At the heart, Mydecine’s core philosophy is that Psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best-accredited research organizations demonstrating its clinical effecti
The fund raise and Dublin listing comes as the company predicts a 10x rise in users over the next two years
The company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification and 100% of Super Smart, a Dutch company building a modern adult-use psychedel
Analysts predict that upcoming regulations would impact the current cannabis market in Canada by as much as $2.45 billion annually by 2023
The Canadian company said it will provide training, protocol development, and ongoing support for the clinic, with the “first patient treatments expected at Seattle Ketamine Infusions in early 2022”
With demand for mental health treatments growing in the face of the coronavirus pandemic, the company sees huge potential to address the need for services with new psychedelic therapies combined with an emphasis on technology
It will first provide its accredited medical cannabis continuing education for pharmacists, then implement its Medical Cannabis Management System in Metro Ontario Pharmacies' pharmacy locations across Ontario